# SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

> **NCT03604679** · PHASE1 · COMPLETED · sponsor: **SymBio Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SyB C-0501

## Key facts

- **NCT ID:** NCT03604679
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-24
- **Primary completion:** 2020-09-11
- **Final completion:** 2020-09-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03604679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03604679, "SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03604679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*